Torrent Pharmaceuticals is trading higher by 3.4% at Rs 498, extending its over 13% rally in past four days, after reporting 33% year-on-year (yoy) growth in adjusted net profit at Rs 149 crore for the second quarter ended September 2013 (Q2) due to higher operational income.
The company has reported a 25.8% yoy rise in net sales to Rs 940 crore on the back of a 31.3% yoy rise in the revenues from the international business partially contributed by currency benefits.
The operating profit margin (OPM) rose by 169 basis points yoy to 19.1% on a higher rupee realisation from international trade and a better product mix.
The company is in the process of expanding its formulation and active pharmaceutical ingredient (API) capacity at Dahej with an investment of Rs 1,100 crore which will help ramp up the product basket for the international markets, says analyst at Sharekhan in its report dated October 31.
The stock opened at Rs 493 and touched 52-week high of Rs 501 on BSE. A combined around 16,000 shares have changed hands on the counter so far on BSE and NSE.
The company has reported a 25.8% yoy rise in net sales to Rs 940 crore on the back of a 31.3% yoy rise in the revenues from the international business partially contributed by currency benefits.
The operating profit margin (OPM) rose by 169 basis points yoy to 19.1% on a higher rupee realisation from international trade and a better product mix.
The company is in the process of expanding its formulation and active pharmaceutical ingredient (API) capacity at Dahej with an investment of Rs 1,100 crore which will help ramp up the product basket for the international markets, says analyst at Sharekhan in its report dated October 31.
The stock opened at Rs 493 and touched 52-week high of Rs 501 on BSE. A combined around 16,000 shares have changed hands on the counter so far on BSE and NSE.